Interactive Features

Quiz

Rovadicitinib for Ruxolitinib-Resistant or Intolerant Myelofibrosis

01/14/2026

True or False: The first-in-class oral JAK/ROCK inhibitor, rovadicitinib, did not demonstrate promising clinical responses or a favorable safety profile among patients with myelofibrosis who were relapsed/refractory or intolerant to prior...

True or False: The...

01/14/2026

Oncology

Quiz

Pelabresib Plus Ruxolitinib for Myelofibrosis

12/01/2025

True or False: The combination of pelabresib and ruxolitinib, compared with ruxolitinib alone, demonstrated negative clinical efficacy and increased symptom burden among patients with myelofibrosis in the phase 3 MANIFEST-2 trial.

True or False: The combination...

12/01/2025

Oncology

Quiz

Imetelstat Combined With Ruxolitinib for Patients With Myelofibrosis

10/28/2025

True or False: According to results from the IMproveMF trial, imetelstat plus ruxolitinib demonstrated a manageable safety profile and promising clinical activity among patients with intermediate-1, intermediate-2, or high-risk myelofibrosis.

True or False: According to...

10/28/2025

Oncology

Quiz

INCB057643 Therapy for R/R Myelofibrosis

09/26/2025

True or False: The small-molecular BET inhibitor INCB057643 demonstrated promising clinical activity and tolerability both as a monotherapy and combined with ruxolitinib for patients with relapsed/refractory myelofibrosis.

True or False: The...

09/26/2025

Oncology

Quiz

Ruxolitinib Combined With Novel Agents for the Treatment of MF

09/12/2025

True or False: According to results from the ADORE clinical trial, ruxolitinib combined with siremadlin treatment demonstrated the least promising safety and efficacy for patients with myelofibrosis, compared with other novel agents in...

True or False: According to...

09/12/2025

Oncology

Quiz

PXS-5505 for the Treatment of Myelofibrosis

05/23/2025

What percentage of patients with relapsed/refractory myelofibrosis treated with novel pan-lysyl oxidase inhibitor PXS-5505 experienced a total symptom score reduction of 20% or more in a phase 1/2a clinical trial?15.3%32%90%62%

What percentage of patients with...

05/23/2025

Oncology

Quiz

Use of Luspatercept for Patients With Myelofibrosis-Associated Anemia

10/16/2024

True or False: According to results from the phase 2, open-label ACE-536-MF-001 trial, luspatercept did not improve anemia and transfusion burden among patients with myelofibrosis-associated anemia with or without both red blood cell...

True or False: According to...

10/16/2024

Oncology

Quiz

Low-Dose Subcutaneous Decitabine Treatment for Patients With MF

10/11/2024

True or False: According to phase 2 prospective study results from a multicenter trial, a high IPSS risk score, high baseline fetal hemoglobin level, and sustained decreases in circulating CD34+ cell counts were associated with a response to...

True or False: According to...

10/11/2024

Oncology

Quiz

Efficacy of Zilurgisertib Alone or Combined With Ruxolitinib in Myelofibrosis

08/22/2024

True or False: According to phase 1/2 results from an ongoing open-label, dose-escalation/expansion study presented at the 2024 European Hematology Association Meeting, zilurgisertib treatment as monotherapy or in combination with ruxolitinib...

True or False: According to...

08/22/2024

Oncology

Quiz

Examining the Efficacy of Azacitidine Plus Ruxolitinib in Myelofibrosis Treatment

07/03/2024

Oncology

Recent News

News

Incidence of Cutaneous Squamous Cell Carcinoma and Carcinoma in Situ Continues to Rise

01/29/2026

Stephanie Holland

Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...

Results from a real-world...

01/29/2026

Oncology

News

Elenagen Plus Gemcitabine Improves Overall Survival for Patients With Platinum-Resistant Ovarian Cancer

01/29/2026

Emily Estrada

The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.

The addition of elenagen to...

01/29/2026

Oncology

News

Axicabtagene Ciloleucel Plus Atezolizumab Demonstrates Promise in Relapsed/Refractory Large B-Cell Lymphoma

01/28/2026

Stephanie Holland

Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.

Results from the phase 1/2...

01/28/2026

Oncology

News

Advances in Antibody-Based Therapies for the Treatment of Relapsed Small-Cell Lung Cancer

01/27/2026

Gina Tomaine

Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.

Antibody-based therapies are...

01/27/2026

Oncology

News

Tucatinib Plus Trastuzumab Shows Durable Efficacy and Manageable Safety for HER2-Posititive Metastatic Colorectal Cancer: MOUNTAINEER Trial

01/27/2026

Emily Estrada

Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.

Tucatinib plus trastuzumab...

01/27/2026

Oncology

News

TOMOX-Bevacizumab Combination Shows Feasibility as Second-Line Therapy in mCRC

01/27/2026

Emily Estrada

A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.

A TOMOX-bevacizumab combination...

01/27/2026

Oncology

News

ISL1 Emerges as a Potential Predictive Biomarker for Efficacy of Lurbinectedin in Relapsed SCLC

01/27/2026

Gina Tomaine

A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.

A translational study identified...

01/27/2026

Oncology

News

CSF-1-Targeted Therapies Continue to Redefine Systemic Treatment for TGCT

01/26/2026

Gina Tomaine

Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.

Systemic CSF-1R inhibition...

01/26/2026

Oncology

News

Sacituzumab Govitecan Plus Pembrolizumab Significantly Prolongs PFS in PD-L1-Positive Triple-Negative Breast Cancer

01/22/2026

Stephanie Holland

Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...

Results from the phase 3...

01/22/2026

Oncology

News

Anbenitamab Plus Chemotherapy After Trastuzumab Failure in HER2-Positive G/GEJ Cancer

01/21/2026

Stephanie Holland

Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...

Results from a multicenter,...

01/21/2026

Oncology